Precision Neuroscience

Name

Precision Neuroscience

Legal name

Precision Neuroscience Corporation

Website

https://precisionneuro.io

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Brain-Computer Interface Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industry

Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)

Keywords

• Brain-computer interface
• Cortical electrode array
• Neural implant technology
• Neuroprosthetic devices
• BCI medical devices

Headquarters

HQ city

Manhattan

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Brain-Computer Interface Medical Devices: Precision Neuroscience is pre-revenue, having received FDA 510(k) clearance in April 2025 for its Layer 7 Cortical Interface. The company is transitioning from clinical development toward commercialization. Future revenue is expected from sale of implantable BCI devices and related surgical/clinical services to healthcare providers and patients with paralysis.
2. Neural Data Services: The company is building and leveraging a neural dataset spanning over 75 patients across multiple brain regions. This neural data has potential applications in drug discovery, AI training, and neurological disease treatment research.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Precision Neuroscience develops and manufactures the Layer 7 Cortical Interface, a non-penetrating brain-computer interface system featuring a 1,024-electrode thin-film microelectrode array designed to be implanted on the brain surface via a minimally invasive micro-slit incision. The system uses AI software to translate neural signals into digital commands, enabling individuals with paralysis to operate computers, speech synthesizers, robotic limbs, and other digital devices using only their thoughts. The company received FDA 510(k) clearance in April 2025 for implantations up to 30 days and sells directly to hospital systems and clinical research institutions.

Product overview

Precision Neuroscience offers a single unified product, the Layer 7 Cortical Interface, a high-resolution brain-computer interface designed to help people with paralysis operate digital devices using only their thoughts. The system uses a non-penetrating surface electrode array with 1,024 electrodes that captures neural signals and translates them into digital commands via AI, enabling thought-based control of computers, speech synthesis, and external devices. The company operates its own 22,000 square foot MEMS fabrication facility in Addison, Texas for manufacturing the microelectrode arrays.

Differentiator

Problem solved

Functional benefit

Products and services

• Layer 7 Cortical Interface A non-penetrating brain-computer interface featuring a 1,024-electrode thin-film microelectrode array on an ultra-thin flexible film thinner than a human hair. The device gently conforms to the brain's surface, is implanted via a minimally invasive micro-slit incision in under 20 minutes, and uses AI software to translate brain signals into digital device commands. Designed for people with paralysis to operate computers, speech synthesizers, robotic limbs, and other digital devices through thought. Wireless, cosmetically discreet, and designed to be safely removable and upgradable without damaging brain tissue.

Quantifiable outcome

• 85+ patients successfully implanted with Layer 7 Cortical Interface across clinical studies
• +4 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature6 records

Partnerships

14 partnerships are on record, tiered core.

• UChicago MedicinecoreStrategic or Co-development Partner · 30 April 2026Clinical partnership with UChicago Medicine's Sensorimotor Bionics Group to advance AI-driven sensorimotor function and neuroprosthetics research using Precision's Layer 7 cortical interface system. The collaboration builds on UChicago Medicine's decade-long involvement in landmark human BCI trials. Research aims to help patients with conditions like ALS or brainstem stroke better understand movement planning and execution, with potential applications in assistive technology and neurorehabilitation.
• MedtroniccoreStrategic or Co-development Partner · 12 January 2026Strategic partnership to integrate Precision's Layer 7 brain-computer interface with Medtronic's StealthStation surgical navigation system. The collaboration aims to provide neurosurgeons with real-time functional and structural brain information during operations by combining Precision's high-resolution electrode technology with Medtronic's 3D surgical navigation platform. The partnership is intended to accelerate clinical adoption of BCI technology and advance neurological care globally.
• WVU Rockefeller Neuroscience InstitutecoreStrategic or Co-development Partner · 21 November 2025Expanded partnership to complete first successful extended in-human clinical study using Layer 7 Cortical Interface, enabling monitoring of brain activity for up to 30 days in patients recovering from craniotomy procedures. The collaboration is supported by a National Science Foundation grant and builds on previous short-term procedures, laying groundwork for fully implantable brain-computer interface systems.
• Beth Israel Deaconess Medical CentercoreStrategic or Co-development Partner · 27 February 2025Clinical research collaboration to expand BCI research using Precision's Layer 7 technology in various clinical settings.
• Mount SinaicoreStrategic or Co-development PartnerClinical partner and co-founding institution. Dr. Benjamin Rapoport, co-founder and Chief Science Officer, is a neurosurgeon at Mount Sinai.
• Penn MedicinecoreStrategic or Co-development PartnerClinical partner for BCI technology research and development.
• Johns Hopkins MedicinecoreStrategic or Co-development PartnerClinical partner for BCI technology research and development.
• Mass General BrighamcoreStrategic or Co-development PartnerClinical partner for BCI technology research and development.
• Northwestern MedicinecoreStrategic or Co-development PartnerClinical partner for BCI technology research and development.
• Emory HealthcarecoreStrategic or Co-development PartnerClinical partner for BCI technology research and development.
• Barrow Neurological InstitutecoreStrategic or Co-development PartnerClinical partner for BCI technology research and development.
• NYU Langone HealthcoreStrategic or Co-development PartnerClinical partner for BCI technology research and development.
• Michigan MedicinecoreStrategic or Co-development PartnerClinical partner for BCI technology research and development.
• Thomas Jefferson UniversitycoreStrategic or Co-development PartnerClinical partner for BCI technology research and development.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Neuralink: Neuralink is the most direct BCI competitor, developing high-bandwidth penetrating electrode implants (N1 chip) for paralysis and other indications. Multiple Precision executives are Neuralink co-founder alumni, and the two are routinely compared head-to-head in media coverage of the BCI category.
• Synchron: Synchron develops the Stentrode, a minimally invasive endovascular BCI that records neural signals via blood vessels, avoiding open brain surgery. Like Precision, it targets paralysis-driven digital device control and has received FDA breakthrough designation, positioning it as the closest clinical-stage alternative to Precision's Layer 7.
• Blackrock Neurotech: Blackrock Neurotech manufactures the Utah Array, a penetrating intracortical electrode used in academic BCI research and human clinical studies for paralysis and speech restoration. It is a direct competitor in the implantable BCI category serving similar patient populations and clinical research sites.
• Paradromics: Paradromics is developing the Connexus BCI, a high-data-rate intracortical implant for restoring speech and communication. It targets the same paralysis and speech-restoration use cases as Precision and is among the cohort of next-generation BCI companies pursuing FDA clinical studies.

Broad incumbents

• Medtronic: Medtronic is Precision's strategic integration partner (StealthStation surgical navigation) and a broad incumbent in neurosurgery and neuromodulation, including the Percept PC deep brain stimulator and Activa platform. Its installed base of neurosurgical navigation systems provides a distribution channel for Precision's Layer 7 and represents the dominant commercial channel in the space.
• Boston Scientific: Boston Scientific is a major neuromodulation incumbent with Vercise deep brain stimulation systems and a broad portfolio in functional neurosurgery. While not a BCI company, it competes in adjacent therapeutic stimulation indications Precision may eventually expand into (Parkinson's, epilepsy, depression).
• Abbott: Abbott operates the Infinity and Proclaim deep brain stimulation and spinal cord stimulation portfolios through its neuromodulation business. It is a broad incumbent in implantable neurostimulation that could compete with or partner alongside Precision in therapeutic indications beyond paralysis.

Emerging players

• InBrain Neuroelectronics: InBrain Neuroelectronics is developing graphene-based neural interfaces for both recording and therapeutic stimulation in CNS disorders. It overlaps with Precision on cortical surface electrode technology and shared indications (Parkinson's, epilepsy) but is at an earlier clinical stage.
• BrainGate: BrainGate is a long-running academic BCI consortium (Brown, MGH, Stanford, Emory, Providence VA) that has demonstrated intracortical control of cursors, robotic arms, and speech in patients with paralysis. It is an emerging competitor/potential partner on the research and clinical validation frontier where Precision also operates.
• Motif Neurotech: Motif Neurotech is developing minimally invasive cortical stimulators for mental health indications such as treatment-resistant depression. It shares Precision's minimally invasive, surface-electrode philosophy and represents an emerging adjacent platform targeting therapeutic neuromodulation via cortical access.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/PrecisionNeuro_
• YouTubeyoutube.com/@PrecisionNeuroscience
• Facebookfacebook.com/PrecisionNeuroscience
• LinkedInlinkedin.com/company/home
• Instagraminstagram.com/precisionneuroscience

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds5 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precision Neuroscience